… safety of adjunctive lacosamide in the treatment of partial‐onset seizures ( POS ) was gained
during placebo‐controlled clinical trials in patients … of adjunctive lacosamide added to one …

… Monotherapy approval of lacosamide in the EU was based on the results of a large-scale,
double-blind trial, which demonstrated that lacosamide … first-line monotherapy in patients with …

… patient taking lacosamide 200 mg/day as monotherapy had a positive pregnancy test and
stopped taking lacosamide … One patient taking lacosamide 400 mg/day as monotherapy had a …

… We report clinical outcomes of lacosamide monotherapy in patients with focal epilepsy…
lacosamide (LCM) monotherapy, as first-line and conversion regimens, in the treatment of patients …

… Our findings suggest that lacosamide is a suitable option for first-line monotherapy in patients
… adjunctive trials of antiepileptic drugs might be extrapolated to the monotherapy setting. …

… patients with epilepsy while lacosamide (LCM), which has been recently approved in European
Union (EU) as monotherapy … of LCM as monotherapy in elderly patients affected by focal …

… Retrospective, non-interventional chart review of lacosamide monotherapy patients aged
≥16 years in Europe. Outcomes included retention rate at observational point (OP) 3 (12 ± 3 …

… We prospectively followed-up consecutive patients converted to lacosamide monotherapy …
-year efficacy and safety of oral lacosamide as conversion monotherapy in adults patients with …

… better seizure control for some of these patients [Luciano and Shorvon, 2007; … safety profile
are needed for use as initial monotherapy as they might be continued for decades in patients …

… safety and efficacy of lacosamide in more than 1300 patients with POS, each randomized to
receive 200, 400, or 600 mg/day lacosamide … Five patients took lacosamide as monotherapy …